A randomized comparative dose-ranging study of interferon-α and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder

BJU International

Volumn 89, Issue 7, 2002, Pages 681-686

  Malmstrom P U ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder neoplasms; Instillation therapy; Mitomycin C and interferon

Indexed keywords

ALPHA INTERFERON; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; VALIDATION PROCESS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 0036228774     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.02734.x     Document Type: Article

References (21)

1. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer
2. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS)
3. 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma
4. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder
5. Chemoresection in Ta-T1 bladder cancer
6. Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma
7. High-dose versus low-dose intravesical interferon-alpha 2b in the treatment of carcinoma in situ: A randomized, controlled study
8. Comparison of two doses of interferon-alpha-2b in intravesical prophylaxis of superficial bladder tumors
9. Efficacy of escalating doses of intravesical interferon-α2b in reducing recurrence rate and progression in superficial transitional cell carcinoma
10. BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study
11. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1). Multicenter trial comparing bacille Calmette-Guerin and interferon-alpha
12. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: Results of a multicentric Italian study
13. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder
14. Transurethral resection with perioperative instillation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: A prospective randomized multi-center study - Finnbladder III
15. A controlled study of intravesical epirubicin with or without α2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder
16. Anti-tumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer
17. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy
18. Salvage intravesical therapy with interferon-alpha2b plus low dose bacillus calmette-guerin is effective in patients with superficial bladder cancer in whom bacillus calmette-guerin alone previously failed
19. Mitomycin-C 30 mg for 12 months versus Mitomycin-C 40 mg for 6 months in the prevention of superficial bladder carcinoma G1-G2
20. Intravesical chemotherapy in the treatment of superficial bladder cancer